This month

SS-31 searches just spiked 47% — and the FDA-approved version has been out since September

Monthly searches for SS-31 jumped 47% in June 2026, which means the longevity and biohacking community has found the peptide again — or more precisely, found it for the first time with a new piece of context to process. On September 19, 2025, the FDA granted accelerated approval to FORZINITY (elamipretide hydrochloride; Stealth BioTherapeutics) for the treatment of Barth syndrome, an ultra-rare X-linked mitochondrial cardiomyopathy affecting an estimated 150 individuals in the United States. The [Stealth BioTherapeutics press release](https://stealthbt.com/stealth-biotherapeutics-announces-fda-accelerated-approval-of-forzinity-elamipretide-hcl-the-first-therapy-for-progressive-and-life-limiting-ultra-rare-genetic-disease-barth-syndrome/) called it the first therapy for the disease. It was also the first FDA-approved mitochondria-targeted drug in history. Forzinity became commercially available through a specialty pharmacy in December 2025. The longevity community that has been discussing SS-31 as an optimization compound for years seems to have largely missed the announcement — understandably, since the press coverage clustered around rare disease advocacy circles rather than the anti-aging and optimization media that normally covers this class of compounds.

The actual biology

This peptide was designed to go inside the mitochondria — all the way to the inner membrane

Elamipretide is a four-amino-acid synthetic tetrapeptide engineered to concentrate at the inner mitochondrial membrane. The key target is cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane that serves as the structural scaffold for the electron transport chain — the machinery responsible for synthesizing ATP. Cardiolipin degrades with age and during disease states involving mitochondrial stress; when it oxidizes or loses structural integrity, the protein complexes of the electron transport chain lose their spatial organization, electron transfer becomes inefficient, reactive oxygen species accumulate, and ATP output falls. SS-31's charge distribution is what makes this targeting possible: the peptide partitions into the inner membrane preferentially, binds cardiolipin, and stabilizes the structural environment in which the respiratory complexes operate. The [PubMed literature on elamipretide](https://pubmed.ncbi.nlm.nih.gov/?term=elamipretide) documents both the pharmacological work that established this targeting mechanism and the clinical development that followed it across rare disease, cardiac, kidney, and aging-adjacent research programs.

What the internet says

The optimization narrative built well before the FDA had a drug on the market

SS-31 accumulated a following in longevity circles through a pharmacological story that maps coherently onto aging biology. Mitochondrial function declines measurably with age. Cardiolipin oxidation is a documented part of that decline. A peptide that targets cardiolipin and stabilizes electron transport chain architecture reads, to a longevity-focused audience, as something close to a precision intervention against a recognized hallmark of aging. That narrative is mechanistically coherent. It is also a story assembled almost entirely outside controlled clinical trial contexts in otherwise-healthy populations. Energy, recovery, cognitive clarity, and age-related decline were not the populations or endpoints of the TAZPOWER trial that took elamipretide to FDA approval. The compound that longevity forums and wellness clinics have been discussing as a self-administered mitochondrial optimization compound and the drug that became commercially available through a rare-disease specialty pharmacy in December 2025 are the same molecule — but they exist in entirely separate regulatory and evidentiary contexts, and the clinical evidence supporting one does not transfer to the other.

What the data says

One approved trial, one missed primary endpoint in heart failure, and ongoing programs in multiple indications

The TAZPOWER clinical trial enrolled patients with confirmed Barth syndrome and evaluated knee extensor muscle strength as the primary endpoint in an open-label phase extending across 36 to 168 weeks. Statistically significant improvements in muscle strength were recorded alongside a mean 96-meter improvement in the 6-minute walk test — the data package supporting the accelerated approval, detailed in the [FDA integrated review for NDA 215244](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000IntegratedR.pdf). Accelerated approval means the evidence base is a validated surrogate endpoint rather than a confirmed direct clinical benefit outcome, with a confirmatory trial requirement still ahead. The contrast with the heart failure program is important context: a Phase 2 randomized placebo-controlled trial of elamipretide in heart failure with reduced ejection fraction, [indexed on PubMed](https://pubmed.ncbi.nlm.nih.gov/29217757/), enrolled 71 participants and evaluated left ventricular end-systolic volume by cardiac MRI — and did not achieve its primary endpoint. Ongoing programs in primary mitochondrial myopathy, heart failure with preserved ejection fraction, kidney disease, and age-related decline are documented on [ClinicalTrials.gov](https://clinicaltrials.gov/search?term=elamipretide). None has produced a second approval.

Human-supported — PeptideFactCheck stance

A real milestone for a real disease — and the optimization audience is a different clinical question

SS-31 / elamipretide holds the Human-supported evidence tier on PeptideFactCheck. The tier's meaning — useful signal, but internet claims may go beyond the data — applies here with uncommon precision. The signal is real: a mechanism with a clear pharmacological basis, a genuine clinical trial in a disease context, and an FDA accelerated approval marking the first approved mitochondria-targeted drug in any indication. The part where internet claims go beyond the data is equally precise. The TAZPOWER trial enrolled patients with an ultra-rare pediatric mitochondrial cardiomyopathy. The surrogate endpoint was knee extensor muscle strength in a population of roughly 150 eligible Americans. The longevity optimization framing — mitochondrial rescue for healthy aging, energy and recovery in otherwise-healthy adults — was not evaluated in that trial. [Fight Aging's coverage of the Forzinity approval](https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/) placed the milestone in the context of mitochondrial aging research while being explicit that elamipretide's clinical track record for optimization claims in healthy adults remains thin. Accelerated approval is the beginning of a regulatory story, not the end of one — confirmatory trials and the ongoing multi-indication program will determine what the evidence tier looks like in a few years. Right now, the FDA stamp is specific. The internet's use of it is not.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.